Fujimoto, Junya
The University of Texas MD Anderson Cancer Center
18 papers on CoChatORCID 0000-0003-4813-3163
Most cited papers
- Verified
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
Liu, J., Lichtenberg, T., Hoadley, K. A., Poisson, L. M., Lazar, A. J., Cherniack, A. D., Kovatich, A. J., Benz, C. C., Levine, D. A., Lee, A. V., et al. (2018) · Cell
Cancer Genomics and DiagnosticsGene expression and cancer classification
Cited by 3,725
- Verified
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 3,201
- Verified
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
Hoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell
Cancer Genomics and DiagnosticsGene expression and cancer classification
Cited by 2,546
- Verified
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell
Cancer Genomics and DiagnosticsGenomics and Rare Diseases
Cited by 2,256
- Verified
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018) · Cell
Cancer Cells and MetastasisPluripotent Stem Cells Research
Cited by 2,180
- Verified
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., et al. (2014) · Science
Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations
Cited by 965
- Verified
Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer
Sen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., et al. (2019) · Cancer Discovery
Cancer Immunotherapy and BiomarkersLung Cancer Research Studies
Cited by 902
- Verified
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
Rimm, D. L., Han, G., Taube, J. M., Yi, E. S., Bridge, J. A., Flieder, D. B., Homer, R., West, W. W., Wu, H., Roden, A. C., et al. (2017) · JAMA Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 764
- Verified
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Cascone, T., William, W. N., Weissferdt, A., Leung, C. H., Lin, H. Y., Pataer, A., Godoy, M. C. B., Carter, B. W., Federico, L., Reuben, A., et al. (2021) · Nature Medicine
Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment
Cited by 618
- Verified
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 552
- Verified
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer
Wang, Y., Xu, X., Maglic, D., Dill, M. T., Mojumdar, K., Ng, P. K.-S., Jeong, K. J., Tsang, Y. H., Moreno, D., Bhavana, V. H., et al. (2018) · Cell Reports
Hippo pathway signaling and YAP/TAZCancer-related molecular mechanisms research
Cited by 500
- Verified
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., et al. (2018) · Cell Systems
Cancer Genomics and DiagnosticsCancer-related Molecular Pathways
Cited by 431
- Verified
Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience
Sholl, L. M., Aisner, D. L., Varella-Garcia, M., Berry, L. D., Dias-Santagata, D., Wistuba, I. I., Chen, H., Fujimoto, J., Kugler, K., Franklin, W. A., et al. (2015) · Journal of Thoracic Oncology
Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics
Cited by 430
- Verified
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
Pietanza, M. C., Waqar, S. N., Krug, L. M., Dowlati, A., Hann, C. L., Chiappori, A., Owonikoko, T. K., Woo, K. M., Cardnell, R. J., Fujimoto, J., et al. (2018) · Journal of Clinical Oncology
Lung Cancer Research StudiesPARP inhibition in cancer therapy
Cited by 399
- Verified
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics
Ding, L., Bailey, M. H., Porta-Pardo, E., Thorsson, V., Colaprico, A., Bertrand, D., Gibbs, D. L., Weerasinghe, A., Huang, K.-L., Tokheim, C., et al. (2018) · Cell
Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer
Cited by 399
- Verified
Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer
Barua, S., Fang, P., Sharma, A., Fujimoto, J., Wistuba, I., Rao, A. U. K., & Lin, S. H. (2018) · Lung Cancer
Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology
Cited by 223
- Verified
Comprehensive T cell repertoire characterization of non-small cell lung cancer
Reuben, A., Zhang, J., Chiou, S.-H., Gittelman, R. M., Li, J., Lee, W.-C., Fujimoto, J., Behrens, C., Liu, X., Wang, F., et al. (2020) · Nature Communications
Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology
Cited by 220
- Verified
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
Aisner, D. L., Sholl, L. M., Berry, L. D., Rossi, M. R., Chen, H., Fujimoto, J., Moreira, A. L., Ramalingam, S. S., Villaruz, L. C., Otterson, G. A., et al. (2018) · Clinical Cancer Research
Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics
Cited by 206
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free